Provider fact sheet · dataset v2026.08.14-4 · last touched 2026-08-14
PlexusDx: GLP-1 programs, prices, and verification status (2026)
PlexusDx lists from $289/month (reported). A diagnostics company selling its own tirzepatide program — injection reported at $289/month, plus an oral protocol at $349 ($279 on 6-month) in the unproven-format bucket — and ranking itself #1 in its own comparison articles.
Programs and pricing, in plain sentences
Compounded tirzepatide (injection) (injectable) is advertised at $289/month — status: reported. Key fields: no membership fee; no commitment required; 12-month total $3,468. Diagnostics company selling its own program and ranking itself #1 in its comparison content — a self-ranking conflict we flag on /review-consensus/. Also lists an oral tirzepatide protocol at $349/mo ($279 on 6-month): unproven format, no human absorption data.
Every figure above carries its status — operator claims come from the provider, reported from third parties we cite, verified only after our own checkout walk. Machine-readable version: providers.json.
Verification status and open items
Current status: reported, last touched 2026-08-14. Open verification items: dispensing pharmacy identity, state coverage map, cancellation terms. Source on file: plexusdx.com. Corrections land within 48 hours via the public log — if your checkout contradicts this page, that report changes the dataset.
How PlexusDx fits the market
A diagnostics company selling its own tirzepatide program — injection reported at $289/month, plus an oral protocol at $349 ($279 on 6-month) in the unproven-format bucket — and ranking itself #1 in its own comparison articles. That self-ranking is the textbook conflict our review-consensus page exists to flag. Where it lands overall: the price ladder, the category winners, and the program finder all compute from the same dataset this page renders.
Advertising disclosure: outbound provider links may be commission-bearing; our partner relationship with NexLife is disclosed on the ownership page and never alters statuses or rankings.